Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study.
Lung cancer in elderly patients poses an increasingly challenge for oncologists. The optimal treatment needs to be explored. The purpose of this study was to evaluate the safety and efficacy of the novel form of paclitaxel liposome for elderly patients with non-small cell lung cancer (NSCLC). This multi-center prospective trial recruited patients aged at least 70 years with advanced or recurrent NSCLC. Eligibility criteria included presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0-2, as well as adequate organ function. Patients received paclitaxel liposome at the escalating dose of 135 mg/m2 , 150 mg/m2 and 175 mg/m2 every three weeks. Forty-two patients were enrolled with a median age of 73 years (range 70-81). No complete response was observed. Partial response was obtained in 6.7%, 14.2% and 7.7% of patients, and 13.3%, 42.9% and 38.5% had stable disease from the three dose groups. In these groups, 26.7%, 21.4% and 25% of patients experienced grade 3-4 neutropenia. Time to progression was 1.2 months (95% confidence interval [CI], 1.1-1.3 months), 1.2 months (95% CI, 0.9-1.3 months) and 1.9 months (95% CI, 1.4-2.3 months), respectively. Overall survival in the dose group of 135 mg/m2 was 4.9 months (95%CI, 1.0-11.5 months) and was not reached in the other two groups. Paclitaxel liposome administered at the dose of 150 mg/m2 every three weeks was the safest and most effective of the three dose levels. However, the treatment achieved only mild effects. It was unnecessary to conduct further phase III randomized trials on this topic.